25 XP   0   0   10

Annexin Pharmaceuticals AB
Buy, Hold or Sell?

Let's analyse Annexin Pharmaceuticals AB together

PenkeI guess you are interested in Annexin Pharmaceuticals AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Annexin Pharmaceuticals AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Annexin Pharmaceuticals AB

I send you an email if I find something interesting about Annexin Pharmaceuticals AB.

Quick analysis of Annexin Pharmaceuticals AB (30 sec.)










What can you expect buying and holding a share of Annexin Pharmaceuticals AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.05
Expected worth in 1 year
kr0.02
How sure are you?
27.6%

+ What do you gain per year?

Total Gains per Share
kr-0.03
Return On Investment
-11.7%

For what price can you sell your share?

Current Price per Share
kr0.28
Expected price per share
kr0.207 - kr0.303
How sure are you?
50%

1. Valuation of Annexin Pharmaceuticals AB (5 min.)




Live pricePrice per Share (EOD)

kr0.28

Intrinsic Value Per Share

kr-0.96 - kr-1.10

Total Value Per Share

kr-0.90 - kr-1.04

2. Growth of Annexin Pharmaceuticals AB (5 min.)




Is Annexin Pharmaceuticals AB growing?

Current yearPrevious yearGrowGrow %
How rich?$1.7m$3m-$1.8m-159.7%

How much money is Annexin Pharmaceuticals AB making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$935.6k-$76.5k-7.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Annexin Pharmaceuticals AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#817 / 1010

Most Revenue
#916 / 1010

Most Profit
#239 / 1010

Most Efficient
#322 / 1010

What can you expect buying and holding a share of Annexin Pharmaceuticals AB? (5 min.)

Welcome investor! Annexin Pharmaceuticals AB's management wants to use your money to grow the business. In return you get a share of Annexin Pharmaceuticals AB.

What can you expect buying and holding a share of Annexin Pharmaceuticals AB?

First you should know what it really means to hold a share of Annexin Pharmaceuticals AB. And how you can make/lose money.

Speculation

The Price per Share of Annexin Pharmaceuticals AB is kr0.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Annexin Pharmaceuticals AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Annexin Pharmaceuticals AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.05. Based on the TTM, the Book Value Change Per Share is kr-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Annexin Pharmaceuticals AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-1.4%0.00-1.0%0.00-1.0%0.00-1.0%0.00-0.9%
Usd Book Value Change Per Share0.001.7%0.00-0.3%0.00-0.4%0.00-0.1%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.001.7%0.00-0.3%0.00-0.4%0.00-0.1%0.000.1%
Usd Price Per Share0.02-0.07-0.08-0.12-0.16-
Price to Earnings Ratio-1.55--6.55--7.72--11.77--20.44-
Price-to-Total Gains Ratio4.96--23.41-8.58--28.75--69.18-
Price to Book Ratio4.79-113.88-9.49-59.34-50.56-
Price-to-Total Gains Ratio4.96--23.41-8.58--28.75--69.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.025732
Number of shares38862
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (38862 shares)-29.21-10.84
Gains per Year (38862 shares)-116.84-43.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-117-1270-43-53
20-234-2440-87-96
30-351-3610-130-139
40-467-4780-173-182
50-584-5950-217-225
60-701-7120-260-268
70-818-8290-303-311
80-935-9460-347-354
90-1052-10630-390-397
100-1168-11800-434-440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.029.00.00.0%0.029.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.021.00.027.6%8.021.00.027.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.021.00.027.6%8.021.00.027.6%

Fundamentals of Annexin Pharmaceuticals AB

About Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation. Annexin Pharmaceuticals AB (publ) was founded in 2014 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2024-04-11 00:40:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Annexin Pharmaceuticals AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Annexin Pharmaceuticals AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Annexin Pharmaceuticals AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y--449.1%+449.1%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Annexin Pharmaceuticals AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • -54.4% Return on Assets means that Annexin Pharmaceuticals AB generated kr-0.54 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Annexin Pharmaceuticals AB:

  • The MRQ is -54.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -50.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-54.4%TTM-50.2%-4.2%
TTM-50.2%YOY-26.3%-23.9%
TTM-50.2%5Y-44.2%-6.0%
5Y-44.2%10Y-36.2%-8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-54.4%-13.3%-41.1%
TTM-50.2%-12.8%-37.4%
YOY-26.3%-11.7%-14.6%
5Y-44.2%-13.9%-30.3%
10Y-36.2%-15.7%-20.5%
1.1.3. Return on Equity

Shows how efficient Annexin Pharmaceuticals AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • -77.3% Return on Equity means Annexin Pharmaceuticals AB generated kr-0.77 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Annexin Pharmaceuticals AB:

  • The MRQ is -77.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -477.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-77.3%TTM-477.2%+399.9%
TTM-477.2%YOY-31.1%-446.2%
TTM-477.2%5Y-186.7%-290.5%
5Y-186.7%10Y-136.2%-50.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-77.3%-16.9%-60.4%
TTM-477.2%-16.1%-461.1%
YOY-31.1%-15.1%-16.0%
5Y-186.7%-19.3%-167.4%
10Y-136.2%-20.2%-116.0%

1.2. Operating Efficiency of Annexin Pharmaceuticals AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Annexin Pharmaceuticals AB is operating .

  • Measures how much profit Annexin Pharmaceuticals AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Annexin Pharmaceuticals AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y--492.1%+492.1%
10Y--632.4%+632.4%
1.2.2. Operating Ratio

Measures how efficient Annexin Pharmaceuticals AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Annexin Pharmaceuticals AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y-5.739-5.739
10Y-7.876-7.876

1.3. Liquidity of Annexin Pharmaceuticals AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Annexin Pharmaceuticals AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.13 means the company has kr3.13 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Annexin Pharmaceuticals AB:

  • The MRQ is 3.134. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.746. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.134TTM2.746+0.388
TTM2.746YOY6.203-3.457
TTM2.7465Y5.942-3.196
5Y5.94210Y5.898+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1343.890-0.756
TTM2.7464.173-1.427
YOY6.2035.344+0.859
5Y5.9426.126-0.184
10Y5.8986.448-0.550
1.3.2. Quick Ratio

Measures if Annexin Pharmaceuticals AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • A Quick Ratio of 3.03 means the company can pay off kr3.03 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Annexin Pharmaceuticals AB:

  • The MRQ is 3.025. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.662. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.025TTM2.662+0.363
TTM2.662YOY6.125-3.463
TTM2.6625Y4.912-2.250
5Y4.91210Y4.502+0.410
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0253.514-0.489
TTM2.6623.998-1.336
YOY6.1255.380+0.745
5Y4.9126.105-1.193
10Y4.5026.404-1.902

1.4. Solvency of Annexin Pharmaceuticals AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Annexin Pharmaceuticals AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Annexin Pharmaceuticals AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Annexin Pharmaceuticals AB assets are financed with 29.7% credit (debt) and the remaining percentage (100% - 29.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Annexin Pharmaceuticals AB:

  • The MRQ is 0.297. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.485. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.297TTM0.485-0.188
TTM0.485YOY0.153+0.331
TTM0.4855Y0.259+0.225
5Y0.25910Y0.244+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2970.339-0.042
TTM0.4850.336+0.149
YOY0.1530.271-0.118
5Y0.2590.366-0.107
10Y0.2440.389-0.145
1.4.2. Debt to Equity Ratio

Measures if Annexin Pharmaceuticals AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 42.3% means that company has kr0.42 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Annexin Pharmaceuticals AB:

  • The MRQ is 0.423. The company is very able to pay all its debts with equity. +2
  • The TTM is 6.455. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ0.423TTM6.455-6.033
TTM6.455YOY0.182+6.273
TTM6.4555Y1.713+4.742
5Y1.71310Y1.268+0.444
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4230.388+0.035
TTM6.4550.402+6.053
YOY0.1820.335-0.153
5Y1.7130.426+1.287
10Y1.2680.461+0.807

2. Market Valuation of Annexin Pharmaceuticals AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Annexin Pharmaceuticals AB generates.

  • Above 15 is considered overpriced but always compare Annexin Pharmaceuticals AB to the Biotechnology industry mean.
  • A PE ratio of -1.55 means the investor is paying kr-1.55 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Annexin Pharmaceuticals AB:

  • The EOD is -1.668. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.549. Based on the earnings, the company is expensive. -2
  • The TTM is -6.551. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.668MRQ-1.549-0.119
MRQ-1.549TTM-6.551+5.002
TTM-6.551YOY-7.718+1.167
TTM-6.5515Y-11.775+5.224
5Y-11.77510Y-20.437+8.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.668-2.264+0.596
MRQ-1.549-2.629+1.080
TTM-6.551-2.680-3.871
YOY-7.718-4.145-3.573
5Y-11.775-6.257-5.518
10Y-20.437-6.254-14.183
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Annexin Pharmaceuticals AB:

  • The EOD is -1.923. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.785. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.393. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.923MRQ-1.785-0.137
MRQ-1.785TTM-6.393+4.608
TTM-6.393YOY-7.635+1.241
TTM-6.3935Y-11.965+5.571
5Y-11.96510Y-16.915+4.950
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.923-2.973+1.050
MRQ-1.785-3.333+1.548
TTM-6.393-3.553-2.840
YOY-7.635-5.605-2.030
5Y-11.965-8.376-3.589
10Y-16.915-8.865-8.050
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Annexin Pharmaceuticals AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.79 means the investor is paying kr4.79 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Annexin Pharmaceuticals AB:

  • The EOD is 5.158. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.790. Based on the equity, the company is fair priced.
  • The TTM is 113.876. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.158MRQ4.790+0.368
MRQ4.790TTM113.876-109.086
TTM113.876YOY9.494+104.382
TTM113.8765Y59.342+54.534
5Y59.34210Y50.561+8.780
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.1581.896+3.262
MRQ4.7902.115+2.675
TTM113.8762.093+111.783
YOY9.4942.884+6.610
5Y59.3423.542+55.800
10Y50.5613.916+46.645
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Annexin Pharmaceuticals AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.052-0.008+116%-0.012+123%-0.003+106%0.002+2702%
Book Value Per Share--0.0540.037+48%0.095-43%0.074-27%0.082-34%
Current Ratio--3.1342.746+14%6.203-49%5.942-47%5.898-47%
Debt To Asset Ratio--0.2970.485-39%0.153+94%0.259+15%0.244+22%
Debt To Equity Ratio--0.4236.455-93%0.182+132%1.713-75%1.268-67%
Dividend Per Share----0%-0%-0%-0%
Eps---0.042-0.032-24%-0.029-30%-0.030-28%-0.027-35%
Free Cash Flow Per Share---0.036-0.031-14%-0.030-18%-0.028-23%-0.027-26%
Free Cash Flow To Equity Per Share--0.029-0.007+124%-0.009+130%0.011+174%0.010+187%
Gross Profit Margin--0.9900.998-1%1.000-1%1.000-1%1.000-1%
Intrinsic Value_10Y_max---1.098--------
Intrinsic Value_10Y_min---0.957--------
Intrinsic Value_1Y_max---0.123--------
Intrinsic Value_1Y_min---0.121--------
Intrinsic Value_3Y_max---0.359--------
Intrinsic Value_3Y_min---0.343--------
Intrinsic Value_5Y_max---0.584--------
Intrinsic Value_5Y_min---0.542--------
Market Cap97043520.000+7%90111840.000261670920.000-66%311838954.000-71%436955778.000-79%603409914.703-85%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio5.158+7%4.790113.876-96%9.494-50%59.342-92%50.561-91%
Pe Ratio-1.668-8%-1.549-6.551+323%-7.718+398%-11.775+660%-20.437+1220%
Price Per Share0.280+7%0.2600.755-66%0.900-71%1.261-79%1.741-85%
Price To Free Cash Flow Ratio-1.923-8%-1.785-6.393+258%-7.635+328%-11.965+570%-16.915+847%
Price To Total Gains Ratio5.338+7%4.957-23.405+572%8.583-42%-28.747+680%-69.182+1496%
Quick Ratio--3.0252.662+14%6.125-51%4.912-38%4.502-33%
Return On Assets---0.544-0.502-8%-0.263-52%-0.442-19%-0.362-33%
Return On Equity---0.773-4.772+517%-0.311-60%-1.867+141%-1.362+76%
Total Gains Per Share--0.052-0.008+116%-0.012+123%-0.003+106%0.002+2702%
Usd Book Value--1729006.6001170806.000+48%3040764.225-43%2357712.880-27%2622290.445-34%
Usd Book Value Change Per Share--0.005-0.001+116%-0.001+123%0.000+106%0.000+2702%
Usd Book Value Per Share--0.0050.003+48%0.009-43%0.007-27%0.008-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.003-24%-0.003-30%-0.003-28%-0.002-35%
Usd Free Cash Flow---1159594.200-997206.900-14%-945765.875-18%-893534.510-23%-852451.724-26%
Usd Free Cash Flow Per Share---0.003-0.003-14%-0.003-18%-0.003-23%-0.002-26%
Usd Free Cash Flow To Equity Per Share--0.003-0.001+124%-0.001+130%0.001+174%0.001+187%
Usd Market Cap8918299.488+7%8281278.09624047557.548-66%28657999.873-71%40156235.998-79%55453371.161-85%
Usd Price Per Share0.026+7%0.0240.069-66%0.083-71%0.116-79%0.160-85%
Usd Profit---1336961.200-1012186.600-24%-935679.850-30%-984216.835-26%-879435.466-34%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.005-0.001+116%-0.001+123%0.000+106%0.000+2702%
 EOD+6 -2MRQTTM+17 -13YOY+8 -225Y+11 -1910Y+11 -19

3.2. Fundamental Score

Let's check the fundamental score of Annexin Pharmaceuticals AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.668
Price to Book Ratio (EOD)Between0-15.158
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.025
Current Ratio (MRQ)Greater than13.134
Debt to Asset Ratio (MRQ)Less than10.297
Debt to Equity Ratio (MRQ)Less than10.423
Return on Equity (MRQ)Greater than0.15-0.773
Return on Assets (MRQ)Greater than0.05-0.544
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Annexin Pharmaceuticals AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.352
Ma 20Greater thanMa 500.266
Ma 50Greater thanMa 1000.259
Ma 100Greater thanMa 2000.268
OpenGreater thanClose0.287
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets26,763
Total Liabilities7,949
Total Stockholder Equity18,814
 As reported
Total Liabilities 7,949
Total Stockholder Equity+ 18,814
Total Assets = 26,763

Assets

Total Assets26,763
Total Current Assets24,915
Long-term Assets1,848
Total Current Assets
Cash And Cash Equivalents 21,415
Net Receivables 2,633
Other Current Assets 867
Total Current Assets  (as reported)24,915
Total Current Assets  (calculated)24,915
+/-0
Long-term Assets
Property Plant Equipment 1,166
Intangible Assets 371
Long-term Assets  (as reported)1,848
Long-term Assets  (calculated)1,537
+/- 311

Liabilities & Shareholders' Equity

Total Current Liabilities7,949
Long-term Liabilities0
Total Stockholder Equity18,814
Total Current Liabilities
Accounts payable 4,326
Other Current Liabilities 3,623
Total Current Liabilities  (as reported)7,949
Total Current Liabilities  (calculated)7,949
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock5,736
Retained Earnings -286,211
Other Stockholders Equity 299,289
Total Stockholder Equity (as reported)18,814
Total Stockholder Equity (calculated)18,814
+/-0
Other
Capital Stock5,736
Cash and Short Term Investments 21,415
Common Stock Shares Outstanding 346,584
Liabilities and Stockholders Equity 26,763
Net Debt -21,415
Net Invested Capital 18,814
Net Working Capital 16,967
Property Plant and Equipment Gross 1,794



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
> Total Assets 
0
0
0
23,460
65,357
48,669
43,219
30,849
22,625
58,837
51,431
46,038
38,206
31,916
26,791
16,036
64,452
49,048
39,849
25,158
10,154
20,929
12,765
52,786
42,813
37,252
39,437
36,679
24,436
22,999
15,985
26,763
26,76315,98522,99924,43636,67939,43737,25242,81352,78612,76520,92910,15425,15839,84949,04864,45216,03626,79131,91638,20646,03851,43158,83722,62530,84943,21948,66965,35723,460000
   > Total Current Assets 
0
0
0
22,082
63,999
47,330
41,899
28,155
19,978
56,190
48,831
43,487
35,703
29,461
24,384
13,678
62,142
46,786
37,635
22,897
7,941
18,764
10,648
50,717
40,532
35,019
37,252
33,650
22,443
21,055
14,090
24,915
24,91514,09021,05522,44333,65037,25235,01940,53250,71710,64818,7647,94122,89737,63546,78662,14213,67824,38429,46135,70343,48748,83156,19019,97828,15541,89947,33063,99922,082000
       Cash And Cash Equivalents 
0
0
0
14,450
5,454
34,056
24,831
14,762
5,908
42,445
35,529
30,216
22,767
16,477
11,425
4,263
52,978
39,784
30,807
18,132
3,324
16,239
8,109
49,479
39,072
34,438
36,744
31,114
20,446
17,280
11,305
21,415
21,41511,30517,28020,44631,11436,74434,43839,07249,4798,10916,2393,32418,13230,80739,78452,9784,26311,42516,47722,76730,21635,52942,4455,90814,76224,83134,0565,45414,450000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
195
266
456
356
198
282
154
151
151
1,015
1,277
69
10
1,862
1,344
3,146
2,428
2,633
2,6332,4283,1461,3441,86210691,2771,01515115115428219835645626619500000000000000
       Other Current Assets 
0
0
0
1,385
50,265
1,110
17,068
13,393
14,070
13,745
13,302
13,271
12,936
12,984
12,959
9,415
9,164
7,002
6,828
4,765
4,617
2,525
2,539
1,238
1,460
581
508
0
653
629
356
867
86735662965305085811,4601,2382,5392,5254,6174,7656,8287,0029,1649,41512,95912,98412,93613,27113,30213,74514,07013,39317,0681,11050,2651,385000
   > Long-term Assets 
0
0
0
1,377
1,358
1,339
1,320
2,694
2,646
2,648
2,600
2,551
2,503
2,455
2,407
2,358
2,310
2,262
2,214
2,261
2,213
2,165
2,117
2,069
2,281
2,233
2,185
3,029
1,993
1,944
1,896
1,848
1,8481,8961,9441,9933,0292,1852,2332,2812,0692,1172,1652,2132,2612,2142,2622,3102,3582,4072,4552,5032,5512,6002,6482,6462,6941,3201,3391,3581,377000
       Property Plant Equipment 
0
0
0
0
0
0
0
1,704
1,682
1,660
1,637
1,615
1,592
1,570
1,548
1,525
1,502
1,480
1,458
1,435
1,413
1,390
1,368
1,346
1,323
1,301
1,278
1,256
1,234
1,211
1,189
1,166
1,1661,1891,2111,2341,2561,2781,3011,3231,3461,3681,3901,4131,4351,4581,4801,5021,5251,5481,5701,5921,6151,6371,6601,6821,7040000000
       Intangible Assets 
0
0
0
1,377
1,358
1,339
1,320
990
964
938
913
887
861
835
809
783
758
732
706
680
654
629
603
577
551
525
500
474
448
422
397
371
3713974224484745005255515776036296546807067327587838098358618879139389649901,3201,3391,3581,377000
       Other Assets 
0
0
0
2,755
0
0
0
0
5,293
0
0
0
0
0
0
0
0
0
0
0
0
0
0
146
0
407
407
892
0
0
-1
0
0-1008924074070146000000000000005,29300002,755000
> Total Liabilities 
0
0
0
7,885
17,227
10,796
9,229
6,409
7,172
6,883
4,309
6,188
3,901
3,601
4,945
4,547
6,650
3,838
2,837
4,520
8,574
4,406
4,419
6,059
5,533
5,408
6,363
6,526
4,396
11,528
15,350
7,949
7,94915,35011,5284,3966,5266,3635,4085,5336,0594,4194,4068,5744,5202,8373,8386,6504,5474,9453,6013,9016,1884,3096,8837,1726,4099,22910,79617,2277,885000
   > Total Current Liabilities 
0
0
0
7,157
16,560
10,192
8,687
5,929
6,754
6,529
4,017
5,959
3,734
3,497
4,903
4,547
6,650
3,838
2,837
4,520
8,574
3,406
4,419
6,059
5,533
5,408
6,364
6,526
4,396
11,528
15,350
7,949
7,94915,35011,5284,3966,5266,3645,4085,5336,0594,4193,4068,5744,5202,8373,8386,6504,5474,9033,4973,7345,9594,0176,5296,7545,9298,68710,19216,5607,157000
       Short-term Debt 
0
0
0
250
250
250
250
250
250
250
250
250
250
250
250
227
167
104
42
0
0
0
1,000
0
0
0
0
0
0
0
10,000
0
010,00000000001,00000042104167227250250250250250250250250250250250250000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
250
250
227
167
104
42
0
0
0
1,000
0
0
0
0
0
0
0
10,000
0
010,00000000001,000000421041672272502500000000000000
       Accounts payable 
0
0
0
4,139
6,064
7,820
6,206
2,827
4,078
3,888
951
3,147
1,574
1,294
2,792
2,408
4,948
2,075
1,255
2,900
5,750
1,202
1,390
3,511
3,011
3,605
4,274
3,329
620
3,412
2,371
4,326
4,3262,3713,4126203,3294,2743,6053,0113,5111,3901,2025,7502,9001,2552,0754,9482,4082,7921,2941,5743,1479513,8884,0782,8276,2067,8206,0644,139000
       Other Current Liabilities 
0
0
0
2,768
10,246
2,122
2,231
2,852
2,426
2,391
2,816
2,562
1,910
1,953
1,861
1,912
1,535
1,659
1,540
1,620
2,824
2,204
2,029
2,548
2,522
1,803
2,090
3,197
3,776
8,116
241
3,623
3,6232418,1163,7763,1972,0901,8032,5222,5482,0292,2042,8241,6201,5401,6591,5351,9121,8611,9531,9102,5622,8162,3912,4262,8522,2312,12210,2462,768000
   > Long-term Liabilities 
0
0
0
728
667
604
542
480
418
354
292
229
167
104
42
0
0
0
0
0
0
1,000
0
3,511
3,011
3,605
-1
3,329
620
0
0
0
0006203,329-13,6053,0113,51101,00000000042104167229292354418480542604667728000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
0
0
0
00000000001,000000000000000000000000
> Total Stockholder Equity
0
0
0
15,574
48,130
37,873
33,990
24,439
15,453
51,954
47,122
39,850
34,305
28,315
21,846
11,488
57,802
45,210
37,012
20,638
1,580
16,523
8,346
46,727
37,280
31,844
33,074
30,153
20,040
11,471
635
18,814
18,81463511,47120,04030,15333,07431,84437,28046,7278,34616,5231,58020,63837,01245,21057,80211,48821,84628,31534,30539,85047,12251,95415,45324,43933,99037,87348,13015,574000
   Common Stock
0
0
0
2,870
5,901
5,901
5,895
5,895
5,895
17,683
17,683
17,683
17,683
17,683
17,683
17,683
21,220
21,220
21,220
21,220
21,220
23,527
23,527
27,448
27,448
2,353
2,557
2,679
2,679
2,679
2,679
5,736
5,7362,6792,6792,6792,6792,5572,35327,44827,44823,52723,52721,22021,22021,22021,22021,22017,68317,68317,68317,68317,68317,68317,6835,8955,8955,8955,9015,9012,870000
   Retained Earnings Total Equity00000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,054
149,905
148,906
148,907
148,907
148,907
161,550
161,550
220,909
220,909
252,082
262,753
269,631
269,620
269,620
269,620
0
0269,620269,620269,620269,631262,753252,082220,909220,909161,550161,550148,907148,907148,907148,906149,90599,054000000000000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
29,818
66,788
66,680
66,586
66,586
66,586
99,055
99,055
99,054
99,054
99,055
99,055
99,054
149,905
148,906
148,907
148,907
148,907
170,550
170,550
220,909
220,909
252,082
262,753
269,631
269,620
269,620
269,620
299,289
299,289269,620269,620269,620269,631262,753252,082220,909220,909170,550170,550148,907148,907148,907148,906149,90599,05499,05599,05599,05499,05499,05599,05566,58666,58666,58666,68066,78829,818000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-193
Gross Profit-193-193
 
Operating Income (+$)
Gross Profit-193
Operating Expense-43,846
Operating Income-44,039-44,039
 
Operating Expense (+$)
Research Development36,025
Selling General Administrative12,861
Selling And Marketing Expenses0
Operating Expense43,84648,886
 
Net Interest Income (+$)
Interest Income122
Interest Expense-104
Other Finance Cost-122
Net Interest Income-104
 
Pretax Income (+$)
Operating Income-44,039
Net Interest Income-104
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-44,054-44,024
EBIT - interestExpense = -44,143
-44,054
-43,950
Interest Expense104
Earnings Before Interest and Taxes (EBIT)-44,039-43,950
Earnings Before Interest and Taxes (EBITDA)-43,846
 
After tax Income (+$)
Income Before Tax-44,054
Tax Provision-0
Net Income From Continuing Ops-39,627-44,054
Net Income-44,054
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses44,039
Total Other Income/Expenses Net-15104
 

Technical Analysis of Annexin Pharmaceuticals AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Annexin Pharmaceuticals AB. The general trend of Annexin Pharmaceuticals AB is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Annexin Pharmaceuticals AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Annexin Pharmaceuticals AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.293 < 0.299 < 0.303.

The bearish price targets are: 0.223 > 0.212 > 0.207.

Tweet this
Annexin Pharmaceuticals AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Annexin Pharmaceuticals AB. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Annexin Pharmaceuticals AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Annexin Pharmaceuticals AB. The current macd is 0.00487462.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Annexin Pharmaceuticals AB price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Annexin Pharmaceuticals AB. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Annexin Pharmaceuticals AB price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Annexin Pharmaceuticals AB Daily Moving Average Convergence/Divergence (MACD) ChartAnnexin Pharmaceuticals AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Annexin Pharmaceuticals AB. The current adx is 18.21.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Annexin Pharmaceuticals AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Annexin Pharmaceuticals AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Annexin Pharmaceuticals AB. The current sar is 0.2537732.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Annexin Pharmaceuticals AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Annexin Pharmaceuticals AB. The current rsi is 58.35. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Annexin Pharmaceuticals AB Daily Relative Strength Index (RSI) ChartAnnexin Pharmaceuticals AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Annexin Pharmaceuticals AB. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Annexin Pharmaceuticals AB price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Annexin Pharmaceuticals AB Daily Stochastic Oscillator ChartAnnexin Pharmaceuticals AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Annexin Pharmaceuticals AB. The current cci is 67.79.

Annexin Pharmaceuticals AB Daily Commodity Channel Index (CCI) ChartAnnexin Pharmaceuticals AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Annexin Pharmaceuticals AB. The current cmo is 24.33.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Annexin Pharmaceuticals AB Daily Chande Momentum Oscillator (CMO) ChartAnnexin Pharmaceuticals AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Annexin Pharmaceuticals AB. The current willr is -54.16666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Annexin Pharmaceuticals AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Annexin Pharmaceuticals AB Daily Williams %R ChartAnnexin Pharmaceuticals AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Annexin Pharmaceuticals AB.

Annexin Pharmaceuticals AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Annexin Pharmaceuticals AB. The current atr is 0.02060639.

Annexin Pharmaceuticals AB Daily Average True Range (ATR) ChartAnnexin Pharmaceuticals AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Annexin Pharmaceuticals AB. The current obv is -7,377,180.

Annexin Pharmaceuticals AB Daily On-Balance Volume (OBV) ChartAnnexin Pharmaceuticals AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Annexin Pharmaceuticals AB. The current mfi is 86.45.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Annexin Pharmaceuticals AB Daily Money Flow Index (MFI) ChartAnnexin Pharmaceuticals AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Annexin Pharmaceuticals AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Annexin Pharmaceuticals AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Annexin Pharmaceuticals AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.352
Ma 20Greater thanMa 500.266
Ma 50Greater thanMa 1000.259
Ma 100Greater thanMa 2000.268
OpenGreater thanClose0.287
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Annexin Pharmaceuticals AB with someone you think should read this too:
  • Are you bullish or bearish on Annexin Pharmaceuticals AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Annexin Pharmaceuticals AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Annexin Pharmaceuticals AB

I send you an email if I find something interesting about Annexin Pharmaceuticals AB.


Comments

How you think about this?

Leave a comment

Stay informed about Annexin Pharmaceuticals AB.

Receive notifications about Annexin Pharmaceuticals AB in your mailbox!